Curexa (Curexa -East, LLC), Egg Harbor Township, NJ

Is Curexa (Curexa -East, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Curexa (Curexa -East, LLC) hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Texas State Board of Pharmacy also lists nonresident license 34357 for CUREXA, EGG HARBOR TOWNSHIP, NJ, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 2586 for Curexa, Egg Harbor Township, NJ, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5698 for Curexa - East, LLC, Egg Harbor Township, NJ, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054022050 for CUREXA-EAST LLC, EGG HARBOR TOWNSHIP, NJ, status ACTIVE and license 054018557 for EHT PHARMACY LLC (dba CUREXA), EGG HARBOR TOWNSHIP, NJ, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002412 for CUREXA - EAST LLC, EGG HARBOR TOWNSHIP, NJ, status ACTIVE (CURRENT) and license PCN.0004044 for CUREXA - EAST LLC (dba CUREXA), EGG HARBOR TOWNSHIP, NJ, status CLOSED (WITHDRAWN), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0012709 for Curexa- East, LLC (dba Curexa), EGG HARBOR TOWNSHIP, NJ, status Active and license A9-0000991 for Curexa- East, LLC (dba Curexa), EGG HARBOR TOWNSHIP, NJ, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301010978 for Curexa-East, LLC, Egg Harbor Township, NJ, status Active, as of Nov 10, 2026.

Has Curexa (Curexa -East, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 13, 2023) for Curexa (Curexa -East, LLC). State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Colorado State Board of Pharmacy’s license dataset also lists 3 actions: “CLS Letter of Admonition” dated Jul 14, 2017, case 2017-1242 on nonresident license OSP 5698, “CLS Stipulation” dated Jul 14, 2017, case 2017-1242 on nonresident license OSP 5698 and “CLS Stipulation” dated Sep 30, 2008, case 2009-48 on nonresident license OSP 5698. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Reprimand” dated Sep 22, 2018, case 2017004086 on nonresident license 054018557 and “Fine” dated Sep 22, 2018, case 2017004086 on nonresident license 054018557.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Curexa -East, LLC; Curexa
Former names FDA gives
EHT Pharmacy, LLC
Location
Egg Harbor Township, NJ
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Sep 13, 2023
FDA Data Dashboard inspections
4 inspections: 1 OAI, 2 VAI, 1 NAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 6 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Curexa -East, LLC dba Curexa (formerly EHT Pharmacy, LLC), a 503A facility, with 3 dated actions.

Document
Sep 13, 2023Warning letterWarning Letter Issued 9/13/2023FDA copy (archived)
Sep 9, 2022Form 483483 Issued 09/09/2022FDA copy (archived)
Oct 9, 2020Form 483483 Issued 10/09/2020FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Curexa - East, LLC, Egg Harbor Township, NJ (FEI number 3011761882), matched to this page by exact name, city and state. It lists 4 inspections: 1 OAI, 2 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 5, 2026No Action Indicated (NAI)Drug Quality Assurance (Drugs)30117618821304370
Sep 9, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30117618821179459
Oct 9, 2020Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30117618821131026
Aug 31, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30117618821068498

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 6 numbered observations in all, across 2 inspections ending Oct 9, 2020 to Sep 9, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 29, 2022 to Sep 9, 2022: 3 observations

Firm on the cover
Curexa -East, LLC dba Curexa, 3007 Ocean Heights Ave, Egg Harbor Township, NJ 08234 -7749
FEI number
3011761882
Establishment type on the cover
Producer of non-sterile drug products
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Non-microbial contamination was observed in your production area.

Specifically,

A. We observed blue powder-like residue in several areas of your facility such as:

i.

On 09/02/2022, we observed blue powder-like residue outside of the dedicated rooms used for production of sildenafil, tadalafil, or vardenafil containing <Redacted B4> products. The blue powder-like residue was observed on wall surfaces and along crevices of the wall-mounted air conditioning unit in the "Nonhazardous Compounding <Redacted B4> " room, which is located adjacent to the <Redacted B4> dedicated rooms. The wall-mounteda air conditioning unit is located above and between the table work surfaces and <Redacted B4> hood <Redacted B4>, and remains on to maintain approximately room temperature. No blue colored <Redacted B4> products are produced in the ''Nonhazardous Compounding <Redacted B4>" room. The last time products containing blue coloring were tableted was 08/11/2022. ...

Read the full 483 (PDF on fda.gov)

Observation 2

You produced hazardous drugs without providing adequate cleaning of utensils to prevent cross-contamination.

Specifically,

A. On 09/07/2022, Technician <Redacted B4> did not use a deactivating or decontaminating agent to clean a <Redacted B4> spatula after it was used in the production of Rx <Redacted B4> : HYDROQUINONE 4%/ TRETINOIN 0.025%/HYDROCORTISONE 1 % NOURISIL", in the hazardous product area. The same <Redacted B4> spatula was subsequently used in the production of Rx <Redacted B4>, "C-TESTOSTERONE 178MG7ML". Similar·ly, a <Redacted B4> stirring rod was used in the production of "METHIMAZOLE (ANIMAL)(STOCK)", lot 09072022@<Redacted B4>, and then it was wiped with a paper towel dampened with <Redacted B4> and placed back into a container holding other utensils for use in further production operations. The <Redacted B4> stirring rod is one of <Redacted B4> stirring rods utilized in production of drug products within biological safety cabinet. Quality Department personnel explained that the cleaning process between different hazardous drug products includes wiping work surfaces and utensils with <Redacted B4> as a deactivating and decontaminating agent. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically, on 08/29/2022, we observed naltrexone HCl capsules, lot 0825202226, being produced in the dedicated "Non-Hazardous Compounding <Redacted B4> "room. We observed inconsistent fill heights of the drugs, <Redacted B4> mixture loaded into the individual capsules in the <Redacted B4> capsule machine. Approximately 50 out of <Redacted B4> capsules were filled at a noticeably lower <Redacted B4> fill height than the others.

Inspection Aug 26, 2020 to Oct 9, 2020: 3 observations

Firm on the cover
EHT Pharmacy LLC dba Curexa, 3007 Ocean Heights Ave, Egg Harbor Township, NJ 0823 4-7749
FEI number
3011761882
Establishment type on the cover
Producer of non-sterile drug products
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Non-microbial contamination was observed in your production area.

Specifically, On 8/26/2020, I observed the tableting room had a fine blue dust/residue coating the walls, ceiling, ceiling vent, blender lid, humidifier, air conditioner and a darker accumulation of the blue dust/residue on the wheels of your stationary blender. This blue colored dust/residue, which is generated during the production of tadalafil and sildenafil, was so pervavsive that it had infiltrated into the other production areas of your facility.

On 09/01/2020, the room was reported to be clean, however the blue dust/residue was observed in the humidifier and as a coating on other surfaces.

The blue dust/residue was observed within your Non-Hazardous and Hazardous Rooms. For example, I observed a blue residue inside the unsealed transfer holes that lead to the Hazardous Room. The products compounded in these rooms do not contain blue coloring.

On 09/03/2020, production of Tadalafil 6mg lot PS l was observed in the tableting area. At the same time, in the Hazardous room a hazardous dermatological drug product <Redacted B4> was being produced.

Your firm uses all rooms to produce drug products. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Laboratory analysis of hormone sample determined the strength was below the declared label claim.

Specifically, On 09/01/2020, I observed <Redacted B4> had a failing potency result. The contract testing laboratory notified your furn on 07/14/2020 that the <Redacted B4> test result was 89.6% (Spec: <Redacted B4>). The failing result was confirmed by the contract testing laboratory. The stock drug <Redacted B4> was used in the production of approximately 9 other drug products.

On 09/03/2020, when asked if there was an investigation, the director of regulatory, quality and compliance provided a corrective action document with the date of 07/08/2020 for the failing product. I noted that the date of the corrective action was 6 days before the initial failure was notified (07/14/2020).

The pharmacist-in-charge verified and stated the corrective action had not been conducted for drug produced on 08/12/2020 using the failing <Redacted B4> stock.

[(5) (4) I has a beyond use date of 12/22/2020.

The record <Redacted B4> does not have a weight for the ingredient, <Redacted B4> There was no deviation or investigation into this error. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Buildings used in the processing of a drug product are not maintained in a good state of repair.

Specifically, I observed the wall in the Hazardous room and your compounding equipment cleaning area in disrepair.

For example,

A) I observed that the wall between the tablet compounding room and the Hazardous room has unsealed holes where blue residue/dust was observed. I observed the blue residue/dust on the perimeter of the wall (i.e. ceiling, floor and sides).

B) Equipment found drying near a yellow painted wall. The wall was tom, scratched, discolored and had dry wall exposed.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
34357Non-Resident (Not Located in Texas)CUREXAEGG HARBOR TOWNSHIP, NJActiveNo

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NRP 2586Non Resident PharmacyCurexaEgg Harbor Township, NJActive

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5698OSPCurexa - East, LLCEgg Harbor Township, NJActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054022050LICENSED PHARMACYCUREXA-EAST LLCEGG HARBOR TOWNSHIP, NJACTIVE
054018557LICENSED PHARMACYEHT PHARMACY LLC (dba CUREXA)EGG HARBOR TOWNSHIP, NJCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002412NONRESIDENT PHARMACYCUREXA - EAST LLCEGG HARBOR TOWNSHIP, NJACTIVE (CURRENT)
PCN.0004044NONRESIDENT PHARMACYCUREXA - EAST LLC (dba CUREXA)EGG HARBOR TOWNSHIP, NJCLOSED (WITHDRAWN)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0012709Non Resident PharmacyCurexa- East, LLC (dba Curexa)EGG HARBOR TOWNSHIP, NJActive
A9-0000991Non Resident PharmacyCurexa- East, LLC (dba Curexa)EGG HARBOR TOWNSHIP, NJClosed

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301010978PharmacyCurexa-East, LLCEgg Harbor Township, NJActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.